Eikon Therapeutics Inc.
EIKN evidence brief
What we can confirm
- BioSniper Score:
- 9.1 / 10
- Market Cap:
- $531.6M
- Lead Asset:
- eik1001 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for EIKN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EIKN
Eikon Therapeutics Inc. (EIKN) is a clinical-stage biotechnology company focused on oncology, leveraging a proprietary single-molecule tracking (SMT) platform to develop novel therapies for high-unmet-need cancers.
Key risk: Profitability uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 10 clinical trials for Eikon Therapeutics Inc..
Eikon Therapeutics Inc. (EIKN) is a clinical-stage biotechnology company focused on oncology, leveraging a proprietary single-molecule tracking (SMT) platform to develop novel therapies for high-unmet-need cancers.
- Cash & equivalents of $142.6M as of 2026-06-30 [sec].
- Net income of -$88.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $466.5M as of 2026-06-30 [sec].
- Pipeline includes clinical-stage candidates EIK1001, EIK1003, EIK1004, and EIK1005, and preclinical asset EIK1006 [sec_mda · as of 2026-08-13].
- Company estimates existing cash will fund operations into the second half of 2027 [sec_mda · as of 2026-08-13].
What works
- Leadership includes Dr. Roger M. Perlmutter (Chair and CEO) and Dr. Roy Baynes (CMO), who have a proven track record of developing and commercializing major oncology drugs, including pembrolizumab [sec_mda · as of 2026-05-11].
- The company's proprietary single-molecule tracking (SMT) platform is a differentiated technology for drug discovery [sec_mda · as of 2026-08-13].
- Cash runway is projected into the second half of 2027, providing a multi-year development horizon [sec_mda · as of 2026-08-13].
What to weigh
- The company has never achieved profitability and expects to continue incurring significant losses for the foreseeable future [sec_mda · as of 2026-03-30].
- Expenses are expected to increase substantially as clinical and preclinical programs advance, raising the risk of needing additional capital [sec_mda · as of 2026-08-13].
- The company relies on third-party contract manufacturing organizations (CMOs) and has no internal manufacturing, marketing, or sales organization [sec_mda · as of 2026-05-11].
- Product development carries numerous risks and uncertainties, and the company may never achieve or sustain profitability [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash runway into second half of 2027
“Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditures into the second half of 2027.”
SEC MD&A · August 13, 2026
Leadership track record with pembrolizumab
“Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab”
SEC MD&A · May 11, 2026
Risk of never achieving profitability
“Because of the numerous risks and uncertainties associated with product development, we may never achieve or sustain profitability, and unless we are able to do so, we will need to continue to raise additional capital.”
SEC MD&A · August 13, 2026
Reliance on CMOs and no internal manufacturing
“We do not currently own or operate any manufacturing facilities. We rely on clinical manufacturing organizations, or CMOs, to produce our product candidates”
SEC MD&A · May 11, 2026
Catalyst timeline
- 2018-02-15 · Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Early-phase trial initiation for a candidate (BDB001) that may be related to the company's pipeline; watch for updates on this program.
- 2019-11-21 · Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Atezolizumab in Subjects With Advanced Solid Tumors — Additional combination study for BDB001; results could inform future development decisions.
- 2021-06-22 · Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Later start of another Phase 1 study for BDB001 with pembrolizumab; may indicate expanded or revised trial design.
- 2021-08-30 · A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or An — Phase 2 initiation for BDB001 in patients who progressed on anti-PD-1 therapy; key efficacy readout to monitor.
Risks & what to watch (3)›
Key risks
- Profitability uncertainty — Company may never achieve or sustain profitability; will need to raise additional capital if not [sec_mda · as of 2026-08-13].
- Rising expenses — Expenses expected to increase substantially as pipeline advances, potentially exhausting cash sooner than projected [sec_mda · as of 2026-08-13].
- No internal manufacturing or sales — Relies on third-party CMOs and has no marketing or sales organization, creating operational dependencies [sec_mda · as of 2026-05-11].
What to watch
- Progress of clinical-stage candidates EIK1001, EIK1003, EIK1004, and EIK1005 through trials [sec_mda · as of 2026-08-13].
- Advancement of preclinical asset EIK1006 and ARv7 programs [sec_mda · as of 2026-03-30].
- Ability to raise additional capital as cash runway extends into second half of 2027 [sec_mda · as of 2026-08-13].
- Any regulatory milestones or partnership announcements that could alter the financial outlook.
Sources: Catalysts · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Eikon Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eikon Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.67 · 0% dilution
Lead: Phase 2/Phase 3
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 8.1%
- Days to cover
- 8.0
- Shares short
- 3,313,762
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EIKN short interestFrequently asked questions
What is the AI investment thesis for Eikon Therapeutics Inc.?
Eikon Therapeutics Inc. (EIKN) is a clinical-stage biotechnology company focused on oncology, leveraging a proprietary single-molecule tracking (SMT) platform to develop novel therapies for high-unmet-need cancers.
What is Eikon Therapeutics Inc.'s lead drug candidate?
Eikon Therapeutics Inc.'s most advanced tracked candidate is eik1001 (Phase 2/Phase 3) for NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous).
Who is the CEO of Eikon Therapeutics Inc.?
Dr. Roger M. Perlmutter M.D., Ph.D. is the chief executive officer of Eikon Therapeutics Inc. (EIKN).
Where is Eikon Therapeutics Inc. headquartered?
Eikon Therapeutics Inc. (EIKN) is headquartered in Millbrae, CA, United States.
What therapeutic areas does Eikon Therapeutics Inc. focus on?
Eikon Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.